● Recruiting

Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)

Condition: Breast Cancer · Sponsor: Institut Curie

PhaseNA

Planned participants90

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a prospective validation study, multicenter, open-label, single-arm study, evaluating the concordance between capillary microsampling (using the VAMS Mitra device) and venous sampling in patients undergoing CDK4/6 therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Marie-Emmanuelle Legrier · 0033156245649 · drci.promotion@curie.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Institut Curie Paris	Paris, France	Recruiting
Institut Curie	Saint-Cloud, France	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07491380